Autolus Therapeutics plc

NASDAQ:AUTL

Biotechnology

Healthcare
$1.06 +0.33%

+$0.01 today

Market cap
$282.13M
Beta
2.01
P/E (TTM)
-1.4
EPS (TTM)
-$1.09
52W Low $1.18High $2.70

Volume 2.56M

Average 1.60M

Income Statement

Follow revenue through to earnings.

Revenue

$75.56M

FY 2025 · Annual

+646.7% YoY

Operating Income

-$281.44M

FY 2025 · Annual

Net Income

-$288.20M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.51M6.19M1.7M10.12M75.56M
Cost of Revenue000141.02M96.59M
Gross Profit1.51M6.19M1.7M(130.9M)(21.03M)
Gross Margin100.0%100.0%100.0%-1293.5%-27.8%
Research & Development110.84M117.35M130.48M158.14M128.59M
Selling, General & Admin31.87M31.9M46.75M0131.82M
Operating Expenses141.88M149.09M181.4M110.53M260.41M
Depreciation & Amortization8.46M7.42M6.57M7.72M9.84M
EBITDA(132.48M)(132.24M)(156.77M)(233.07M)(250.26M)
EBITDA Margin-8790.6%-2135.0%-9232.6%-2303.1%-331.2%
Operating Income(140.37M)(142.89M)(179.7M)(241.43M)(281.44M)
Operating Margin-9314.8%-2307.0%-10583.1%-2385.6%-372.4%
Interest Income262K1.71M13.51M32.36M19.02M
Interest Expense1.11M8.91M45.07M9.29M36.76M
Other Income / Expenses(1.66M)(5.67M)(28.7M)22.29M(15.41M)
Income Before Tax(142.04M)(148.57M)(208.4M)(219.13M)(296.85M)
Pre-Tax Margin-9425.2%-2398.6%-12273.4%-2165.4%-392.8%
Income Tax Expense58K272K(19K)1.53M(8.65M)
Net Income(142.1M)(148.84M)(208.38M)(220.66M)(288.2M)
Net Margin-9429.1%-2403.0%-12272.3%-2180.5%-381.4%
EPS (Basic)(1.97)(1.57)(1.20)(0.87)(1.08)
EPS (Diluted)(1.97)(1.57)(1.20)(0.87)(1.08)
Weighted Avg Shares72.08M94.99M173.94M255.16M266.14M
Weighted Avg Shares (Diluted)72.08M94.99M173.94M255.16M266.14M

AUTL Earnings Waterfall · TTM

NASDAQ:AUTL · Revenue to Net Income

Key Ratios

EPS$-1.09
Gross Margin-12.5%
Net Margin-311.8%
P/E Ratio-1.8
P/S Ratio21.3

Analysis

$92.6M of revenue converted into -$288.8M of net income for the selected period. Gross margin is -12.5% and net margin is -311.8%, showing how much revenue survives after costs and taxes. EPS is $-1.09, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-8S-8 filingNov 13, 2026
SC 13G/ASC 13G/A filingNov 12, 2026
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
SC 13D/ASC 13D/A filingNov 10, 2026

How much revenue does AUTL generate?

Autolus Therapeutics plc (AUTL) reported $75.56M of revenue in fiscal 2025.

Is AUTL profitable?

Autolus Therapeutics plc (AUTL) reported -$288.20M of net income, with a net margin of -381.4%.